Skip to main content
CRS 2024 Annual Meeting and Exposition Main banner
Final Program


CRS Abstract Guide
Back

Moein Moghimi, PhD (he/him/his)

Professor of Pharmaceutics and Nanomedicine
Newcastle University
Newcastle-upon-Tyne, United Kingdom

Moein Moghimi is a Professor of Pharmaceutics and Nanomedicine at the School of Pharmacy, and Translational and Clinical Research Institute, Newcastle University (UK), and an Adjoint Professor at the Skaggs School of Pharmacy, University of Colorado, Denver. He is co-founder of S M Discovery Group Inc. and S M Discovery Group Ltd. He further serves as Editor-in-Chief of Drug Delivery (Taylor & Francis) and Associate Editor of Molecular Therapy (the flagship journal of the American Society of Gene and Cell Therapy). He graduated with Honors in Biochemistry from the University of Manchester (UK) in 1985 and completed his PhD in Biochemistry at Charing Cross and Westminster Medical School (Imperial College). He is widely published and reported in the press, and renowned for his ground-breaking contributions to fundamental and translational research in nanomedicine and drug delivery, especially in mechanistic understanding of nanoparticle-mediated complement activation and adverse reactions, and as an inventor of many drug delivery systems for tissue-specific targeting.

Disclosure information not submitted.

Presentation(s):